The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
The product is expected to start contributing meaningfully to the revenue from FY25
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The plant is expected to start commercial operations from Q4FY24
The expansion positions Cambrex with the largest and most advanced API facility in the United States
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Subscribe To Our Newsletter & Stay Updated
